Market capitalization | CHF178.02b |
Enterprise Value | CHF193.43b |
P/E (TTM) P/E ratio | 11.91 |
EV/FCF (TTM) EV/FCF | 14.93 |
EV/Sales (TTM) EV/Sales | 4.51 |
P/S ratio (TTM) P/S ratio | 4.15 |
P/B ratio (TTM) P/B ratio | 4.98 |
Dividend yield | 3.63% |
Last dividend (FY23) | CHF3.30 |
Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.
26 Analysts have issued a Novartis forecast:
26 Analysts have issued a Novartis forecast:
Sep '24 |
+/-
%
|
||
Revenue | 42,905 42,905 |
8%
8%
|
|
Gross Profit | 31,675 31,675 |
3%
3%
|
|
EBITDA | 18,020 18,020 |
10%
10%
|
EBIT (Operating Income) EBIT | 12,708 12,708 |
6%
6%
|
Net Profit | 15,573 15,573 |
117%
117%
|
In millions CHF.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Head office | Switzerland |
CEO | Vasant Narasimhan |
Employees | 76,057 |
Founded | 1996 |
Website | www.novartis.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.